The top-scored drugs predicted to reverse the ReCa gene expression are FDA-approved for cancer treatment, such as the topoisomerase inhibitors (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and teniposide) and the CDK inhibitor (palbociclib) (Figure 3b). Here, RAD51 is linked to cancer.